AbbVie (NYSE:ABBV) Stock Rating Reaffirmed as Outperform by Royal Bank Of Canada

AbbVie (NYSE:ABBV)‘s stock had its “outperform” rating reiterated by research analysts at Royal Bank Of Canada in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $280.00 price target on the stock. Royal Bank Of Canada’s price objective suggests a potential upside of 1.76% from the company’s current price.

Other research analysts have also issued reports about the stock. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. BMO Capital Markets lifted their price objective on shares of AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Argus lifted their price objective on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $225.00 price objective (up from $203.00) on shares of AbbVie in a research note on Tuesday, June 23rd. Finally, Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average target price of $277.18.

AbbVie Stock Performance

NYSE:ABBV traded down $5.96 on Tuesday, hitting $275.16. The stock had a trading volume of 2,100,286 shares, compared to its average volume of 6,391,962. The stock has a market cap of $486.15 billion, a P/E ratio of 77.86, a price-to-earnings-growth ratio of 1.26 and a beta of 0.24. AbbVie has a 1 year low of $190.75 and a 1 year high of $283.43. The firm’s fifty day simple moving average is $259.79 and its two-hundred day simple moving average is $237.39.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter last year, the business posted $2.97 EPS. AbbVie’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts predict that AbbVie will post 13.94 EPS for the current year.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.06% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AbbVie

A number of large investors have recently bought and sold shares of the stock. First County Bank CT boosted its position in AbbVie by 0.4% during the 3rd quarter. First County Bank CT now owns 14,671 shares of the company’s stock valued at $3,838,000 after acquiring an additional 61 shares in the last quarter. Sage Capital Advisors llc boosted its position in AbbVie by 0.4% during the 3rd quarter. Sage Capital Advisors llc now owns 23,552 shares of the company’s stock valued at $6,161,000 after acquiring an additional 96 shares in the last quarter. McGlone Suttner Wealth Management Inc. boosted its position in AbbVie by 0.6% during the 3rd quarter. McGlone Suttner Wealth Management Inc. now owns 12,230 shares of the company’s stock valued at $3,199,000 after acquiring an additional 70 shares in the last quarter. Sivik Global Healthcare LLC boosted its position in AbbVie by 46.7% during the 3rd quarter. Sivik Global Healthcare LLC now owns 22,000 shares of the company’s stock valued at $5,755,000 after acquiring an additional 7,000 shares in the last quarter. Finally, Compass Financial Group INC SD increased its stake in shares of AbbVie by 15.3% during the third quarter. Compass Financial Group INC SD now owns 1,648 shares of the company’s stock valued at $431,000 after purchasing an additional 219 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Fresh clinical and regulatory developments are strengthening AbbVie’s growth narrative. Phase 3 data for SKYRIZI and RINVOQ in Crohn’s disease, along with FDA Breakthrough Therapy Designations for temab-A in colorectal and lung cancer, could expand the company’s long-term commercial opportunities. Early obesity data also add potential upside to the pipeline. AbbVie Could Be 44% Below Fair Value on Fresh Pipeline Wins
• Positive Sentiment: Long-term data presented at ACG 2026 continue to support the durability and growth prospects of SKYRIZI and RINVOQ. Analysts expect the two therapies to offset part of Humira’s revenue erosion and drive third-quarter top-line growth. AbbVie Highlights Long-Term SKYRIZI and RINVOQ Data
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and assigned a $280 price target, indicating continued confidence in AbbVie’s earnings outlook despite limited near-term upside at current levels.
• Neutral Sentiment: Recent coverage highlights AbbVie as an attractive income stock after market weakness pushed its dividend yield higher. That may support defensive and income-oriented demand, though the yield increase also reflects recent selling pressure. High-Yield Dividend Stocks
• Negative Sentiment: At a lofty valuation following a substantial rally, investors may be taking profits while assessing whether SKYRIZI and RINVOQ can fully replace Humira sales. Rising competition in immunology and the stock’s limited analyst-implied upside are additional near-term headwinds. Will SKYRIZI and RINVOQ Drive AbbVie’s Top-Line Growth?

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.